GLP-1 Market Key Players AstraZeneca Boehringer Ingelheim D&D Pharmatech Eli Lilly Hanmi Pharmaceutical Novo Nordisk Pfizer Roche Sanofi Tonghua Dongbao Pharmaceutical GLP-1 Pipeline Phases The GLP-1 agonists industry is evolving with key players advancing candidates through clinical stages for obesity, diabetes, and cardiometabolic indications
And obesity is not great for Alzheimer's risk
And be sure to drink lots of water (48 to 64 ounces a day), too, as fiber absorbs water to make stools easier to pass
Obesity leads to a constant state of low-grade inflammation, which not only makes arthritis pain and swelling worse but also raises your risk for diabetes, heart attacks, and even early death
These statements reflect the brand's description and are not clinical findings for the finished product
It has been widely explored in studies relating to muscle recovery, tendon repair, and systemic healing responses